Apogee Therapeutics, Inc. (APGE) Stock Score, Valuation & Financial Research

Apogee Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for APGE

Apogee Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 135.07. These figures are a research snapshot, not a buy or sell recommendation.

What Apogee Therapeutics, Inc. does

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Apogee Therapeutics is a clinical-stage biotechnology company that does not currently generate product revenue. Its business model relies on developing proprietary antibody programs to treat inflammatory and immunology diseases, with the goal of eventually commercializing these candidates following successful clinical trials and regulatory approval.

Products and services

  • The company is developing a pipeline of antibody candidates, including APG777 and APG990, designed to treat conditions such as atopic dermatitis, asthma, and eosinophilic esophagitis by targeting well-established mechanisms of action.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for clinical trial management, preclinical studies, and the manufacturing of its product candidates. Source

Business relationships and partnerships

  • Paragon Therapeutics, Inc. — A related party that performs ongoing research and development and other services for the company under an antibody discovery and option agreement. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various established and emerging biopharmaceutical companies that are developing therapies for inflammatory and immunology diseases. Source

Business strengths to evaluate

  • Advanced antibody engineering platform designed to optimize half-life and other therapeutic properties. Source

Business risks and research considerations

  • Limited operating history and lack of product revenue. Source
  • High dependence on third-party collaborators and service providers for clinical development and manufacturing. Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

APGE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 135.07
Market capitalization:
8.4B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -294.37M
Free cash flow:
USD -232.6M
Cash:
USD 105.57M
Total debt:
USD 6.83M
EPS:
USD -4.34

What stands out

  • Free cash flow is USD -232.6M, negative for the stored period.
  • The balance sheet shows USD 105.57M of cash versus USD 6.83M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 98.74M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for APGE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can APGE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is APGE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for APGE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of APGE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research APGE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.